Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocol.

Arif A. et al, (2023), BMC Public Health, 23

Phylogenetic Analysis of Hepatitis C Virus Infections in a Large Belgian Cohort Using Next-Generation Sequencing of Full-Length Genomes.

Christensen KT. et al, (2023), Viruses, 15

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV.

Cargill T. et al, (2023), JHEP Rep, 5

Joint statement in support of hepatitis C human challenge studies.

Alter HJ. et al, (2023), Lancet Gastroenterol Hepatol, 8, 967 - 969

Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and in liver transplant recipients.

Murray SM. et al, (2023), J Hepatol

Correction to: Patient Biochemistry and Treatment Need in Chronic Hepatitis B Virus Infection Across Three Continents: Retrospective Cross-Sectional Cohort Studies.

Gillespie IA. et al, (2023), Infect Dis Ther

CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study.

Neale I. et al, (2023), mBio

Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history.

Hornsby H. et al, (2023), Nat Commun, 14

Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study.

Hamill V. et al, (2023), BMJ, 382

Patient Biochemistry and Treatment Need in Chronic Hepatitis B Virus Infection Across Three Continents: Retrospective Cross-Sectional Cohort Studies.

Gillespie IA. et al, (2023), Infect Dis Ther

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.

Barnes E. et al, (2023), Nat Med, 29, 1760 - 1774

Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination.

Johnson SA. et al, (2023), Clin Exp Immunol, 212, 249 - 261

An enrichment protocol and analysis pipeline for long read sequencing of the hepatitis B virus transcriptome.

Ng E. et al, (2023), J Gen Virol, 104

Disparities in care and outcomes for primary liver cancer in England during 2008-2018: a cohort study of 8.52 million primary care population using the QResearch database.

Liao W. et al, (2023), EClinicalMedicine, 59

The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.

Murray SM. et al, (2023), Nat Rev Immunol, 23, 304 - 316

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults.

Green C. et al, (2023), Clin Exp Immunol, 211, 269 - 279

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.

Moore SC. et al, (2023), Med, 4, 191 - 215.e9

Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.

Dijokaite-Guraliuc A. et al, (2023), Cell Rep, 42

Pan-genotypic probe-based enrichment to improve efficiency of Hepatitis B virus sequencing

Lumley SF. et al, (2023)

CD4+ and CD8+ T cell and antibody correlates of protection against Delta vaccine breakthrough infection: A nested case-control study within the PITCH study

Neale I. et al, (2023)

Load More

1
2
3
4
5
6
7
...
»